Keywords: biolex, acquire, lemnagene, therapeutics, venture, capital-backed, clinical
Biolex to acquire LemnaGene
Article | 01 August 2005
Biolex Therapeutics, a US venture capital-backed, clinical development-stage protein therapeutics company, has announced the acquisition of LemnaGene SA, a privately-held, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
